2026 Winner • Influential Businesswoman Awards
AAVantgarde Bio
—
Nina (Ekaterini) Kotsopoulou
—
Leading Gene Therapy Innovation Leader 2026 (London): Nina (Ekaterini) Kotsopoulou
Scroll to keep reading
AAVantgarde Bio
—
Nina (Ekaterini) Kotsopoulou
—
Leading Gene Therapy Innovation Leader 2026 (London): Nina (Ekaterini) Kotsopoulou
Nina Kotsopoulou is the CTO at AAVantgarde, a clinical stage biotechnology company pioneering next generation of best-in-class therapies for patients with inherited retinal diseases due to mutations in large genes. AAVantgarde's proprietary dual AAV technology addresses the root cause of these diseases. The company’s lead programs target Stargardt disease and retinitis pigmentosa due to Usher syndrome type 1B, two severe, inherited retinal diseases with no approved treatments.
Our Trusted Brands
Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.
